I found this part of the study in the discussion section interesting
These findings demonstrate that inclusion of DNA in the vaccine is critical to improve the longevity of responses. We report herein the maintenance of Env bAb in macaques for more than 3 years after the last vaccination. These data are corroborated by our previous report that SIV DNA only vaccination with IM/EP delivery is able to induce long-lasting (2 years) immune responses to Gag and Nef in macaques , which were boosted with each subsequent immunization, even after an extended 90-week rest period, indicating long-lasting memory responses. In a follow-up of some of these animals, we found an impressive durability of the Gag responses for 5 years. The remarkable longevity of the immune responses elicited by EP-delivered DNA vaccines extends data from another study with 1-year follow-up showing persistence of Env humoral responses in EP DNA vaccinated macaques . The co-immunization regimen benefits from the inclusion of both vaccine components, eliciting both long-lasting humoral and cellular immune responses. Thus, the immunity induced by the co-immunization regimen is distinct from that obtained with replicating viral vectors like recombinant CMV, which provides robust, long-lasting SIV-specific CTL without inducing SIV-specific antibodies , . Both recombinant CMV as well as DNA-based vaccines induced potent CTL responses able to efficiently control viremia for long periods of time , , . However, in contrast to recombinant CMV vector, the DNA&Protein co-immunization also induces potent long-lasting systemic humoral immunity able to disseminate into mucosal surfaces and significantly reduce virus acquisition .
Together, our data show that a vaccine protocol combining DNA and protein elicits the most potent responses in macaques, characterized by persistent and efficient cellular immune responses  and the highest levels of functional humoral immune responses with remarkable longevity. Such properties may prove essential for the improvement of AIDS vaccines. Thus, this study supports a role of DNA and protein based vaccines for development of an efficacious HIV/AIDS vaccine.
good summary taken from results-Taken together, these data show that the robust broad antibody responses elicited by DNA only vaccination could be increased by vaccine regimens including either DNA as prime followed by protein boost or, most importantly, co-immunization of DNA&protein, a regimen that combines the benefit of both vaccine modalities and induces highest and broadest bAb and NAb responses.
I always love a new INO find..they always sneak them in there, looks like a nice collaboration on this study
About the Authors
Rashmi Jalah, Viraj Kulkarni, Candido Alicea, Barbara K. Felber
Human Retrovirus Pathogenesis Section, National Cancer Institute, Frederick, Maryland, United States of America
Vainav Patel, Margherita Rosati, Jenifer Bear, Antonio Valentin, George N. Pavlakis
Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, United States of America
Lei Yu, Yongjun Guan
Institute of Human Virology, Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, United States of America
Xiaoying Shen, Georgia D. Tomaras
Duke Human Vaccine Institute and Departments of Surgery and Immunology, Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, United States of America
Celia LaBranche, David C. Montefiori
Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America
Rajasekhar Prattipati, Abraham Pinter
Public Health Research Institute, University of Medicine and Dentistry of New Jersey, Newark, New Jersey, United States of America
Julian Bess Jr, Jeffrey D. Lifson
AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America
Steven G. Reed
Infectious Disease Research Institute, Seattle, Washington, United States of America
Niranjan Y. Sardesai
Inovio Pharmaceuticals, Inc., Blue Bell, Pennsylvania, United States of America
David J. Venzon
Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America
We tested the concept of combining DNA with protein to improve anti-HIV Env systemic and mucosal humoral immune responses. Rhesus macaques were vaccinated with DNA, DNA&protein co-immunization or DNA prime followed by protein boost, and the magnitude and mucosal dissemination of the antibody responses were monitored in both plasma and mucosal secretions. We achieved induction of robust humoral responses by optimized DNA vaccination delivered by in vivo electroporation. These responses were greatly increased upon administration of a protein boost. Importantly, a co-immunization regimen of DNA&protein injected in the same muscle at the same time induced the highest systemic binding and neutralizing antibodies to homologous or heterologous Env as well as the highest Env-specific IgG in saliva. Inclusion of protein in the vaccine resulted in more immunized animals with Env-specific IgG in rectal fluids. Inclusion of DNA in the vaccine significantly increased the longevity of systemic humoral immune responses, whereas protein immunization, either as the only vaccine component or as boost after DNA prime, was followed by a great decline of humoral immune responses overtime. We conclude that DNA&protein co-delivery in a simple vaccine regimen combines the strength of each vaccine component, resulting in improved magnitude, extended longevity and increased mucosal dissemination of the induced antibodies in immunized rhesus macaques.
Inovio has trial data they could pr now but have choose not to for whatever reason, I trust managements timing, so far they've executed well. I imagine the offering and institutional buying have had something to do with it.
It must be american english spelling also, someone on here translate the data for steve when it comes out
They made the late breaking abstract date of jan 27th...which yes had to go through a sub committee and have an aacr sponsor
The deadline for submission of late-breaking abstracts was Monday, January 27. Abstracts detailing highly significant and timely findings in any area of cancer research that were not available at the time of the regular abstract deadline were considered by the AACR Annual Meeting Program Committee for presentation at the AACR Annual Meeting 2014. Only those abstracts that were deemed to be of high scientific priority have been accepted. A special subcommittee of the Program Committee evaluated the merit of late-breaking abstracts. Each late-breaking abstract must have been sponsored by an AACR member.
Authors who submitted abstracts confirm that they have not previously published these data, that they have not previously presented them at a large national annual scientific meeting, and that they are not planning to present or publish them prior to the dates of the AACR Annual Meeting 2014. Each abstract should have contained: (a) an introductory sentence indicating the purposes of the study; (b) a brief description of pertinent experimental procedures; (c) a summary of the new, unpublished data; and (d) a statement of the conclusions. Authors must accept sole responsibility for the statements in their abstracts. Abstract submitters were asked to carefully proofread to avoid errors in the published literature and to use American English spelling throughout. For more information regarding American English spelling, please refer to Scientific Style and Format:
Session Title: Late-Breaking Research: Immunology
Session Type: Late-Breaking Poster Session
Session Start/End Time: Tuesday, Apr 08, 2014, 1:00 PM - 5:00 PM
Abstract Number: LB-257
Presentation Title: Immunoadjuvant ISG15 enhances human papillomavirus 16 antigen-specific cell-mediated antitumor immunity
Presentation Time: Tuesday, Apr 08, 2014, 1:00 PM - 5:00 PM
Location: Hall A-E, Poster Section 41
Author Block: Daniel Villarreal, Megan C. Wise, Jian Yang, David B. Weiner. University of Pennsylvania, Philadelphia, PA, Inovio Pharmaceuticals, Blue Bell, PA